home / stock / arvn / arvn quote
Last: | $24.85 |
---|---|
Change Percent: | 0.35% |
Open: | $25.89 |
Close: | $24.85 |
High: | $26.04 |
Low: | $24.62 |
Volume: | 416,486 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$24.85 | $25.89 | $24.85 | $26.04 | $24.62 | 416,486 | 07-02-2024 |
$25.98 | $26.62 | $25.98 | $26.805 | $25.841 | 765,898 | 07-01-2024 |
$26.62 | $25.77 | $26.62 | $26.74 | $25.5 | 4,058,951 | 06-28-2024 |
$25.85 | $25.83 | $25.85 | $26.1 | $25.08 | 1,081,702 | 06-27-2024 |
$25.87 | $24.42 | $25.87 | $26.58 | $24.35 | 1,090,622 | 06-26-2024 |
$24.46 | $24.98 | $24.46 | $24.985 | $23.7301 | 1,178,529 | 06-25-2024 |
$24.97 | $25.25 | $24.97 | $25.59 | $24.64 | 542,002 | 06-24-2024 |
$25.22 | $25.54 | $25.22 | $26.23 | $24.945 | 1,804,782 | 06-21-2024 |
$25.3 | $24.51 | $25.3 | $25.35 | $24.01 | 790,497 | 06-20-2024 |
$24.82 | $24.79 | $24.82 | $25.23 | $24.59 | 653,623 | 06-19-2024 |
$24.82 | $24.79 | $24.82 | $25.23 | $24.59 | 653,623 | 06-18-2024 |
$24.94 | $25.51 | $24.94 | $25.6 | $24.49 | 744,893 | 06-17-2024 |
$25.67 | $26.06 | $25.67 | $27.055 | $25.075 | 745,024 | 06-14-2024 |
$26.45 | $26.41 | $26.45 | $26.84 | $25.65 | 787,969 | 06-13-2024 |
$26.49 | $27.47 | $26.49 | $28.05 | $26.32 | 722,147 | 06-12-2024 |
$26.29 | $26.76 | $26.29 | $27.1 | $26 | 575,178 | 06-11-2024 |
$26.99 | $26.44 | $26.99 | $27.09 | $26.04 | 581,668 | 06-10-2024 |
$26.69 | $27.13 | $26.69 | $27.71 | $26.21 | 544,156 | 06-07-2024 |
$27.7 | $27.86 | $27.7 | $28.37 | $27.53 | 755,205 | 06-06-2024 |
$27.93 | $29.45 | $27.93 | $30.12 | $27.51 | 1,593,496 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...
– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the Biennial International LRRK2 Meeting high...
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, P...